H.E. Mohamed Hassan Alsuwaidi, Chief Executive Officer of ADQ, said: “Our long-term ambition for ADQ’s healthcare and pharma portfolio is to create a provision-centred, digitally enhanced ecosystem that is anchored in world-class clinical excellence, effective population health management and resilient supply chain infrastructure. While we anticipate this will unlock shareholder value, it will also, importantly, deliver positive socio-economic impact with better health outcomes, optimized healthcare spend and more opportunities for local and international talent.”
His Excellency added: “We are well on our way to building out a supply chain that ensures greater accessibility of healthcare and pharma products and supplies for the people of Abu Dhabi and beyond. As a local producer of generic medication, Pharmax will provide us with a high-quality facility, deep sector knowledge and strong relationships for growing pharma manufacturing in the UAE. Biocon Biologics proven R&D track record, manufacturing scale and commercial partnerships worldwide provide us with an opportunity to benefit from the biosimilar sector that is set to grow as patents of originator biologics expire and patients demand lower priced drugs globally.”
Leading Global Biopharmaceutical Company Enabling Affordable Access
Biocon Limited is an innovation-led, global biopharmaceuticals company that develops and commercializes novel biologics, biosimilars, and complex generic APIs & formulations in India and several key global markets including the US and Europe. The company is committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, oncology and immunology.
Biocon Biologics Limited, a subsidiary of Biocon Limited, is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world. The company is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. Five molecules from Biocon Biologics’ biosimilars portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan. The company is committed to impact millions of patients across the globe. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. With a multi-cultural team of over 4,500 people, Biocon Biologics aspires to transform healthcare through affordable innovative solutions as well as impact 5 million patients’ lives by FY 22.
Dr. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, said: We welcome ADQ as our investment partner as we pursue our shared goal of expanding access to high quality affordable biopharmaceuticals to patients across the globe. We are committed to pursue our affordable innovation model to generate savings for the healthcare systems worldwide. This investment is an endorsement of the value that Biocon Biologics business has built as a fully integrated pure-play biosimilars company and will enable us to expand our capabilities further.”
UAE-Based, State-of-the-Art Manufacturer
Pharmax specializes in manufacturing and packaging branded generic products, mainly of small molecule and oral solid dosage (OSD) pharmaceuticals across a wide range of therapeutic areas such as cardiology, diabetes, gastroenterology and neurology. Pharmax has batch release approvals for various other dosage forms such as injectables, inhalers, topical and liquid orals. Launched in April 2020, the company’s state-of-the-art facility has a total area of more than 110,000 sq. ft. with installed production capacity of more than 250 million tablets and 85 million capsules annually. Pharmax received its first GMP approval from the UAE Ministry of Health and Prevention in 2019, and is one of only a few facilities in the UAE that has been approved by the European Union Good Manufacturing Practices (EU GMP).
Madhukar Tanna, Chief Executive Officer of Pharmax Pharmaceuticals, commented: “We established Pharmax with the belief that patients all over the world deserve access to affordable, effective medications. Joining forces with ADQ will allow us to increase the availability of locally manufactured, quality, affordable generic and complex drugs. At the same time, we will have greater opportunities to increase availability of pharmaceuticals in the UAE while further expanding our distribution in the region.”
Both transactions are subject to customary closing conditions, including regulatory approvals.
Established in Abu Dhabi in 2018, ADQ is one of the region's largest holding companies with direct and indirect investments in more than 90 companies locally and internationally. Both an asset owner and investor, ADQ’s broad portfolio of major enterprises span key sectors of a diversified economy, including energy and utilities, food and agriculture, healthcare and pharma, and mobility and logistics, amongst others. As a strategic partner of Abu Dhabi’s government, ADQ is committed to accelerating the transformation of the emirate into a globally competitive and knowledge-based economy.
For more information, visit adq.ae or write to email@example.com . You can also follow ADQ on Twitter, Instagram and LinkedIn.
About Pharmax Pharmaceuticals
Pharmax Pharmaceuticals provides access to affordable, branded generic medication. Committed to exceeding the expectations of healthcare providers, practitioners and patients, Pharmax Pharmaceuticals offers a diverse range of medications across a wide range of therapeutic areas. Pharmax Pharmaceuticals is a GMP-licensed international manufacturer and distributor of high-quality medications into most regulated markets globally. Pharmax Pharmaceuticals is committed to maintaining a culture of quality and its state-of-the-art facility meets stringent local and global regulatory standards. www.pharmax.ae
About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013), is headquartered in Bangalore, India. It is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex generic APIs and formulations in India and several key global markets including the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.
Website: www.biocon.com ; Follow-us on Twitter: @bioconlimited
About Biocon Biologics Limited
Biocon Biologics Limited, a subsidiary of Biocon Limited, is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world. Building on the four pillars of Patients, People, Partners and Business, Biocon Biologics is committed to transforming healthcare and transforming lives. Biocon Biologics is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. Five molecules from Biocon Biologics’ portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan.
© Press Release 2021